Skip to main content

Table 3 Comparison of clinicopathologic characteristics among the subgroups

From: Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

Variable

Subgroup 1

(n = 141)

Subgroup 2

(n = 51)

Subgroup 3

(n = 99)

Subgroup 4

(n = 154)

P 1

P 2

P 3

P 4

Age (years)

0.290a

0.042a

0.108a

0.526a

 Mean ± SDb

48.4 ± 10.6

46.6 ± 9.6

50.7 ± 11.9

47.6 ± 11.7

 <50

78

33

41

87

 ≥50

63

18

58

67

Gender

0.216

0.527

0.988

0.092

 Males

124

48

87

131

 Females

17

3

12

23

HBeAg

0.011

<0.001

0.441

0.360

 Positive

42

6

25

10

 Negative

99

45

74

144

Tumor size (cm)

0.233a

0.922a

0.158a

0.020a

 Mean ± SDb

4.8 ± 3.1

4.2 ± 2.8

5.4 ± 3.1

5.5 ± 3.3

 <5

86

36

45

76

 ≥5

55

15

54

78

Tumor number

0.460

0.194

0.278

0.360

 Single

131

45

88

144

 Multiple

10

6

11

10

Pathologic grade

0.561

0.375

0.498

0.444

 I

10

2

12

9

 II

85

36

56

94

 III

45

13

30

50

 IV

1

0

1

1

Microvascular thrombus

0.756

0.210

0.430

0.273

 Yes

19

6

10

9

 No

122

45

89

145

Tumor capsule (cases)

0.083

0.729

0.056

0.648

 Complete

64

23

43

69

 Incomplete

49

11

24

42

 Without

28

17

32

43

Liver cirrhosis

0.017

0.738

0.852

0.012

 Yes

101

45

72

109

 No

40

6

27

45

AFP (ng/mL)

0.216

0.514

0.897

0.523

 ≤25

61

17

42

59

 >25

80

34

57

95

ALT (IU/L)

0.052a

<0.001a

0.485a

0.220a

 Mean ± SDb

52.4 ± 29.3

42.8 ± 32.1

49.8 ± 26.0

36.8 ± 22.3

 ≤40

53

30

46

104

 >40

88

21

53

50

AST (IU/L)

0.009a

0.008a

0.508a

0.596a

 Mean ± SDb

44.4 ± 27.1

33.7 ± 16.8

42.4 ± 17.6

35.5 ± 21.6

 ≤45

96

42

62

127

 >45

45

9

37

27

ALB (g/L)

0.028a

0.092a

0.372a

0.168a

 Mean ± SDb

42.8 ± 3.5

44.1 ± 3.7

42.3 ± 4.0

43.2 ± 3.9

 <35

2

1

95

150

 ≥35

139

50

4

4

TBIL (μmol/L)

0.931a

0.878a

0.114a

0.193a

 Mean ± SDb

16.0 ± 7.8

15.9 ± 5.8

14.5 ± 5.4

14.6 ± 5.8

 ≤20.5

116

40

84

133

 >20.5

25

11

15

21

Prothrombin time (s)

0.929a

0.182a

0.824a

0.345a

 Mean ± SDb

12.7 ± 1.5

12.7 ± 1.6

12.6 ± 1.3

12.4 ± 1.2

 ≤13.5

101

38

76

131

 >13.5

40

13

23

23

Recurrence

0.535

0.001

0.180

0.312

 Yes

79

26

64

66

 No

62

25

35

88

Death

0.189

0.001

0.731

0.276

 Yes

41

10

48

42

 No

100

41

51

112

  1. Definition of the four subgroups: (1) subgroup 1, antiviral therapy and baseline HBV DNA ≥ 2000 IU/mL (n = 141); (2) subgroup 2, antiviral therapy and baseline HBV DNA <2000 IU/mL or undetectable (n = 51); (3) subgroup 3, non-antiviral therapy and baseline HBV DNA ≥2000 IU/mL (n = 99); and (4) subgroup 4, non-antiviral therapy and baseline HBV DNA <2000 IU/mL or undetectable (n = 154)
  2. P 1 P value calculated by comparing subgroup 1 and subgroup 2, P 2 P value calculated by comparing subgroup 3 and subgroup 4, P 3 P value calculated by comparing subgroup 1 and subgroup 3, P 4 P value calculated by comparing subgroup 2 and subgroup 4, Antiviral group resection plus postsurgical antiviral treatment group, Non-antiviral group resection alone group, HBV hepatitis B virus, SD standard deviation, HBeAg hepatitis B e antigen, TNM tumor-node-metastasis, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALB serum albumin, TBIL serum total bilirubin
  3. a t test used
  4. b Except for these values, other values are presented as the number of patients and were compared by the χ2 test